Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

VESTAR SUBMITS NOTICE OF TERMINATION FOR R&D AGREEMENT WITH LYPHOMED

Executive Summary

VESTAR SUBMITS NOTICE OF TERMINATION FOR R&D AGREEMENT WITH LYPHOMED "due to the inability of the parties to agree regarding key aspects of the research to be carried out by the partnership," Vestar said. In a Sept. 27 press release, Vestar maintained that communications between the two companies "have been poor and that LyphoMed has been unwilling to hold discussions concerning the differences between the parties." LyphoMed announced the joint venture to develop liposome formulations of designated drugs using Vestar's liposome carrier technology in March 1987 ("The Pink Sheet" March 27, 1987, T&G-3). Under the agreement, the two companies were to equally fund all R&D projects, with Vestar retaining manufacturing rights and LyphoMed responsible for sales and marketing. Profits and expenses from the joint venture were to be split equally. The lead compound covered by the joint venture is a liposomal formulation of doxorubicin (Adria's Adriamycin), which is in Phase II clinicals at Georgetown University. A liposomal formulation of amphotericin B, in preclinicals, is also covered by the agreement. "The partnership between Vestar and LyphoMed provides that if it is terminated, the two companies are to agree on the distribution of partnership assets," Vestar said. The San Dimas, Calif.-based liposome company said that if agreement is not reached within 60 days, "the matter will be submitted to arbitration as provided in the partnership agreement." Vestar President Roger Crossely stated: "We would have liked to sit down with them and try to work things out, but under the circumstances it appears best that we go our separate ways." In addition to the LyphoMed partnership, Vestar has collaborative research agreements with J&J's Ethicon division for development of a post-surgical wound healing agent, with Genentech for development of a therapeutic protein delivery system, with Bristol-Myers on a targeted version of cisplatin, and with Sandoz for targeting immunomodulating drugs.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS014388

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel